Skin gel targets immune signals in rare lymphoma
Disease control
Not yet recruiting
This early-phase trial tests a topical gel containing duvelisib, a drug that blocks certain immune signals, in people with early-stage mycosis fungoides — a type of skin lymphoma. The study enrolls about 30 participants with stage IA to IIA disease who have 3 to 5 accessible skin…
Phase: PHASE1 • Sponsor: SecuraBio • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC